This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.





Esmaiel Jabbari ▼

Professor, Chemical Engineering, Biomedical Engineering, University of South Carolina

Esmaiel Jabbari completed his Ph.D. in Chemical Engineering, Purdue University in 1993. He is Tenured Full Professor of Chemical and Biomedical Engineering at the University of South Carolina. He directs the Biomaterials, Tissue Engineering, and Drug Delivery Laboratory which specializes in 3D tissue models for engineering of skeletal tissues and targeted drug delivery to cancer stem cells.

Prof. Jabbari has received numerous awards for his research achievements including the Berton Rahn Award in 2012 from the AO Foundation and the Stephen Milam Award in 2008 from the Oral and Maxillofacial Surgery Foundation. He was elected to the College of Fellows of American Institute of Medical and Biological Engineering (AIMBE) in 2013. He is the author of >250 refereed articles and he has mentored >130 scholars. He serves as Academic Editor for PLOS ONE and he is the Programming Chair for Bionanotechnology theme of the Engineering in Medicine & Biology Society (EMBS).



Chair, sub-committee for clinical oncology

Dr. Anil K. Sood is Professor and Vice Chair for Translational Research in the Department of Gynecologic Oncology and Reproductive Medicine at the UT MD Anderson Cancer Center. He holds a joint appointment in Cancer Biology and is co-director of the Center for RNA Interference and Non-Coding RNA at the M. D. Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program and co-leads the Ovarian Cancer Moonshot Program. 

Dr. Sood received his medical degree from the University of North Carolina, Chapel Hill. A major and consistent theme of his scientific research has been on understanding human cancer biology and converting lab discoveries into novel therapeutics. His research group has made several seminal research contributions in the fields of tumor microenvironment, nanomedicine, and neuroendocrine effects on cancer biology. Dr. Sood has received recognition for his research accomplishments including the Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher. He is an elected member of the American Society for Clinical Investigation (ASCI), the American Association for the Advancement of Science (AAAS), and the Association of American Physicians (AAP). Dr. Sood was selected as an American Cancer Society Research Professor in 2017.



Professor Pharmaceutical Sciences Division, School of Pharmacy, Carbone Comprehensive Cancer Center, School of Medicine and Public Health, University of Wisconsin Madison 

Dr. Seungpyo Hong is Professor of Pharmaceutics in the Pharmaceutical Sciences Division, School of Pharmacy at the University of Wisconsin-Madison (UW-Madison). He also holds an appointment as Adjunct Professor in the College of Pharmacy at the University of Illinois at Chicago (UIC) and serves as Associate Editor for Nanomedicine: Nanotechnology, Biology and Medicine of Elsevier.  He graduated from Hanyang University in Seoul, Korea with B.S. and M.S. degrees in polymer engineering in 1999 and 2001, respectively.

After working as a researcher at Korea Institute Science and Technology (KIST), he started his Ph.D. study at the University of Michigan working with his advisors Profs. Mark Banaszak Holl and James Baker, Jr.  Dr. Hong graduated with his PhD in Macromolecular Science and Engineering in 2006 and joined MIT as a postdoctoral associate in the laboratory of Prof. Robert Langer. From 2008 to 2014, he was Assistant Professor at UIC where he was promoted to Associate Professor in 2014, and subsequently joined the UW-Madison faculty as Professor in 2016.

Since 2008, he has led a research group under the major research theme of “Biomimetic Nanotechnology” for cancer treatment. To date, Prof. Hong’s research has culminated in over 68 peer-reviewed articles that have combined total citations of ~10,000 times, 7 book chapters, and 15 issued or pending patents


DR. Abhijit Date ▼

Assistant Professor of Pharmaceutical Sciences, Daniel K. Inouye College of Pharmacy, University of Hawaii Hilo

Abhijit Date, M.Pharm., Ph.D. is an Assistant Professor at the Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii Hilo. His research work is focused on exploring applications of nanomedicine for the prevention and/or treatment of cancer, infectious diseases and inflammatory disorders. He received his M.Pharm., and Ph.D. in Pharmaceutics from Bombay College of Pharmacy, University of Mumbai, India. His doctoral work focused on the development of novel self-assembled lipid nanocarriers for improved oral delivery of drugs and natural products.

During Ph.D., he was also selected as a part of Institute of Chemical Technology team that represented India at the Indo‐UK Biotechnology YES (Young Entrepreneurship Scheme) at Oxford, United Kingdom. After graduation, he joined the Chemistry of Life Processes Institute, Northwestern University as a post-doctoral fellow. He received an additional post-doctoral training at the School of Pharmacy and Health Professions, Creighton University and at The Center for Nanomedicine at Johns Hopkins University School of Medicine. He received the Johns Hopkins Center for Nanomedicine research excellence award in 2016. He has 40 peer-reviewed publications and 1 book chapter to his credit. His research work has resulted in the filing of 4 US patents. .


Dr. Brian Aguado ▼

Postdoctoral Fellow, Anseth Research Group, University of Colorado

Dr. Brian Aguado is currently an NIH and Burroughs Wellcome Fund postdoctoral fellow at the University of Colorado. His current research is focused on developing precision biomaterials for applications in personalized medicine. Brian completed his MS and PhD in biomedical engineering from Northwestern University and his BS degree in biomechanical engineering from Stanford University. He also obtained his certificate in Management for Scientists and Engineers from the Kellogg School of Management at Northwestern.

Brian is also a dedicated science communicator outside of the lab and seeks to engage underrepresented populations in the sciences. He has served as president of the Postdoctoral Association of Colorado, a seminar series coordinator for CU Café, and currently serves as the CU Boulder Representative for Project Bridge.



Assistant Professor of Biomedical Engineering, Weldon School of Biomedical Engineering

Hyowon (Hugh) Lee received his B.A. in neuroscience from Colorado College in 2004 and his M.S. and Ph.D. degrees in biomedical engineering from the University of California, Los Angeles, in 2008 and 2011, respectively. Before joining Purdue, he worked as a senior engineer for St. Jude Medical’s Implantable Electronics Systems Division where he focused on using advanced fabrication technologies to overcome manufacturing challenges associated with implantable electronic devices such as pacemakers, ICDs, DBS, and other neurostimulation devices.

At UCLA, he trained in the areas of neuroengineering and microfabrication to develop novel implantable magnetic microactuators for hydrocephalus patients. His current research interests include development and translation of implantable micro and nanosystemsfor neurological application, MEMS-cell interface for cancer research, and safety and reliability of implantable neurostimulation devices 


Dr. Niren Murthy ▼

Professor, Department of Bioengineering, Murthy Lab Department of Bioengineering

Niren Murthy is a professor in the Department of Bioengineering at the University of California at Berkeley. Dr. Murthy’s laboratory is an interdisciplinary laboratory that focuses on the development of new materials for drug delivery and molecular imaging. Dr. Murthy received the NSF CAREER award in 2006, and the 2009 Society for Biomaterials Young Investigator Award. The Murthy laboratory has developed several new biomaterials for drug delivery and molecular imaging, such as the hydrocyanines.


Dr. Bianca Cerqueira ▼

Co-founder, NovoThelium

Dr. Cerqueira is the Co-founder and President of NovoThelium, a biotechnology company developing a tissue based matrix for nipple regeneration after mastectomy. Dr. Cerqueira completed her Ph.D. in Biomedical Engineering at University of Texas Health Science Center at San Antonio/University of Texas at San Antonio, where her dissertation work investigated the ability of melatonin to ameliorate effects of chronic intermittent hypoxia (a model of sleep apnea) on stroke in rodents utilizing multimodal MRI including cASL f-MRI, resting CBF imaging, and diffusion weighted imaging. She also holds a certificate in Translational Science from UT Health San Antonio.

She has a Bachelor of Science in Physiology and Neurobiology from University of Maryland, where she began her career in science at Walter Reed Army Institute of Research in the Department of Casualty Research studying blood additive solutions.


Dr. Kimberly Hamad-Schifferli ▼

Associate Professor of Engineering, University of Massachusetts Boston
Kimberly Hamad-Schifferli received her SB in Chemistry in 1994 from the Massachusetts Institute of Technology, where she did research with Robert W. Field. She did her graduate work in the Department of Chemistry at the University of California at Berkeley with Paul Alivisatos studying the surface properties of semiconductor nanocrystals using surface sensitive spectroscopic techniques. She received her Ph.D. in Chemistry in 2000. She did postdoctoral work with Joe Jacobson at the MIT Media Lab from 2000 to 2002. In 2002 she joined the faculty in the Department of Mechanical Engineering and the Department of Biological Engineering at MIT where she held the chairs of the Homer A. Burnell Professor and an Esther and Harold E. Edgerton Professor. From 2012 to 2015 she was technical staff at MIT Lincoln Laboratory.


In 2015 she joined the University of Massachusetts Boston as an Associate Professor in the Department of Engineering. She received the Office of Naval Research Young Investigator Award (ONR YIP) in 2004 and the Ruth and Joel Spira Award for Distinguished Teaching in Engineering at MIT. She is a long-time member of the American Chemical Society, and has served on the Chair of the Biophysical Subdivision of the Physical Chemistry Executive Committee of the ACS. She is also a member of the Materials Research Society. Her work investigates the physical interface of nanoparticles with biomolecules, exploring the fundamental properties of nanoparticle-protein, nanoparticle- DNA interactions, and nanoparticle protein coronas, in addition to developing applications that exploit the interface for triggered release from gold nanoparticles and nanorods and rapid diagnostics for infectious disease that use gold and silver nanoparticles.


Dr. Steve Shih ▼

Assistant Professor, Electrical and Computer Engineering, Universite Concordia University Montreal
Steve completed his BASc in Electrical Engineering from the University of Toronto and then went to University of Ottawa to complete his Master’s degree in Chemistry. He then returned to Toronto to complete his Ph.D in Biomedical Engineering in Aaron Wheeler’s laboratory working with microfluidics for biological and medical applications. He then spent two years at UC Berkeley and at the Joint BioEnergy Institute as a postdoctoral researcher under the supervision of Dr. Jay Keasling and Dr. Nathan Hillson where he learned pathway engineering and synthetic biology. As of 2016, he is an Assistant Professor at Concordia University in the Department of Electrical and Computer Engineering with a cross-appointment in the Department of Biology and is an affiliate member of the Center for Applied Synthetic Biology.


Dr. Mervi Heiskanen ▼

Program Manager, Center for Biomedical Informatics & Information Technology,National Cancer Institute
Mervi Heiskanen received her Ph.D. in human genetics from the University of Helsinki, Finland. Prior to joining the NCI Mervi was developing high throughput microarray based technologies as a Senior Scientist at Compugen Inc. and a Visiting Fellow at the NIH Human Genome Research Institute. At CBIIT she is the lead for the NCIP Hub collaboration tool, and caNanoLab database that supports management and sharing of nanotechnology data. She also supports the Informatics Technology of Cancer Research (ITCR) Program, a trans-NCI program developing informatics technologies to support basic and translational cancer research.


Dr. Christine Ogilvie Hendren ▼

Executive Director, Center for the Environmental Implications of NanoTechnology (CEINT), Duke University, Durham North Carolina
Dr. Christine Ogilvie Hendren is a Research Professor in Civil and Environmental Engineering at Duke University, and Executive Director of the Center for the Environmental Implications of NanoTechnology (CEINT). Dr. Hendren co-chairs the National Cancer Informatics Program’s Nanotechnology Working Group, as well as the US-EU Nanomaterial Environment, Health and Safety Community of Research on Risk Assessment. She also founded and chairs the Intereach (Interdisciplinary Integration Research Careers Hub) community of practice. Her research focuses on human and data aspects of methods for synthesizing knowledge across boundaries, particularly in complex and emerging fields with pervasive uncertainty.


Dr. Andrew Wang ▼

Associate Professor and Director of Clinical and Translational Research, Department of Radiation Oncology, UNC-Chapel Hilla
Andrew Z. Wang, MD, is Associate Professor and Director of Clinical and Translational Research, Department of Radiation Oncology, UNC-Chapel Hill. He is also the co-Director of the Carolina Cancer Nanotechnology T32 training program. Dr. Wang earned his undergraduate degrees from Indiana University and medical degree from the HST program at Harvard Medical School. He completed his radiation oncology training in the Harvard Radiation Oncology Program. Following residency, Dr. Wang joined the UNC faculty in 2009. Dr. Wang’s research program is focused on the clinical translation of engineering sciences, including Nanomedicine, to oncology. His research spans a wide spectrum of translational research, from preclinical research to early phase clinical trials. He also co-founded Capio Biosciences, a biotech startup that is translating a nanotechnology-based circulating tumor cell capture assay.

 Back To Top